Digitoxin Fails in Heart Failure Trial 09/01/25

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 1 key cardiology studies on topics like Cardiovascular Mortality and Hospitalization.. Key takeaway: Biomarker-guided treatments show no outcome benefits. Article Links: Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. (The New England journal of medicine) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/digitoxin-fails-in-heart-failure-trial-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879434 Summary: This double-blind, placebo-controlled trial investigated digitoxin’s efficacy in chronic Heart Failure with Reduced Ejection Fraction patients with left ventricular ejection fraction of 40 percent or less and a New York Heart Association functional class of III or IV, or a left ventricular ejection fraction of 30 percent or less and an NYHA functional class of II. The study did not show a significant difference between digitoxin and placebo groups regarding the primary composite outcome of death from cardiovascular causes or hospitalization for heart failure, suggesting digitoxin is not beneficial in this patient population. Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. This double-blind, placebo-controlled trial investigated digitoxin’s efficacy in chronic Heart Failure with Reduced Ejection Fraction patients with left ventricular ejection fraction of 40 percent or less and a New York Heart Association functional class of III or IV, or a left ventricular ejection fraction of 30 percent or less and an NYHA functional class of II. The study did not show a significant difference between digitoxin and placebo groups regarding the primary composite outcome of death from cardiovascular causes or hospitalization for heart failure, suggesting digitoxin is not beneficial in this patient population. Thank you for listening. Tap ‘more’ for full notes and links. Keywords Cardiovascular Mortality, Hospitalization., Heart Failure with Reduced Ejection Fraction, Digitoxin, Cardiac Glycosides. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Digitoxin Fails in Heart Failure Trial 09/01/25 first appeared on Cardiology Today.